However, in more recent years, some anti-tumor drugs under investigation are involving tumor metabolism, e.g. by reducing glucose availability as metformin [35], or by directly targeting glycolysis proteins [36]; our results suggest that in clinical investigations on these drugs, GAPDH levels in resected NSCLC samples should be investigated as possible predictor of treatment effectiveness. Here, GAPDH is linked to non-small cell lung carcinoma.